polatuzumab vedotin,rituximab,cyclophosphamide,doxorubicin,vincristine,prednisolone,methotrexate
roche
['lymsm', 'pola', 'lymphoma']
5-yr results primeur-ivl trial (only trial in intravascular lymphoma) #17icml:
- rchop + iv and it mtx
- 37 pts (68% age&gt;60, 22% hlh, many ecog 2-3)
- 5-yr pfs 68%, os 78% (!!!)
- 1 pt developed cns relapse
really impressive in a rare &amp; tough disease to treat. pola next? #lymsm 
Lymphoma doc & patient-reported outcomes researcher in #lymsm and #mmsm @CUHematology. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. 🏳️‍🌈